Please assess the completion status of the following clinical trial:

Trial Title: Immediate Anterior Chamber Paracentesis With A 30-Gauge Needle for Acute Primary Angle - Closure

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients aged more than 18 year old with the first attack of APAC~* IOP of more than or equal to 40 mmHg.~Exclusion Criteria:~* patient unable to cooperate for paracentesis~* patients with APAC in the only remaining eye~* patients received any glaucoma treatments prior to the study~* patients with secondary causes of acute angle closure~* patients with intraocular inflammation or infection; (6) patients with APAC in the eye with a history of previous intraocular surgery~* patients known hypersensitive to tetracaine hydrochloride or tobramycin.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paracentesis (Type: EXPERIMENTAL): Immediate anterior chamber paracentesis (ACP) with a 30-gauge needle as an initial treatment for acute primary angle closure.~Acetamide, given in this study, is a standard treatment for acute angle-closure glaucoma. The participant will receive 1 tablet(250mg) at 1 hours after paracentesis. The following dose will be adjusted according to the level of IOP. The maximal dose is 4 tablets per day. It will be discontinued if the IOP is less than 21 mmHg.~All affected eyes will receive laser peripheral iridotomy with 24 hours after presentation. This a standard treatment for Acute angle-closure glaucoma

Based on this trial design, predict the completion outcome and termination type (if applicable).